Beyond Air Revenue Reaches $2.324 Million, Setting Company’s Highest Quarterly Record
Key Facts
Beyond Air reported revenue of $2.324 million for the quarter ended September 30, 2026, compared with $1.818 million in the year-earlier period. The company said the revenue marked its highest quarterly level in its history. Revenue grew about 28% year over year and 31% compared with the quarter ended June 30, 2026. Meanwhile, the company posted a net loss attributable to shareholders of $7.818 million. The results put sales growth alongside continued losses, as the company maintained its revenue outlook for the next two years.
Basic and diluted loss per share was $3.76 for the quarter, compared with $24.98 in the same period of 2025. Net loss declined from $7.940 million to $7.818 million between the periods. The comparison shows a modest improvement in total net loss alongside higher revenue. The company’s announcement did not include a verified figure for how much the loss per share exceeded analysts’ expectations. Nor did it state how much revenue exceeded market estimates. The reported loss per share remains a separate measure from the year-over-year comparison of total net loss.
Research and development expenses fell to $1.6 million from $2.5 million a year earlier. The company attributed the decline mainly to lower development costs for its second LungFit PH system, as most of the development work on it had been completed. Selling, general and administrative expenses declined to $4.6 million from $4.9 million in the year-earlier period. The company said lower stock-based compensation costs contributed to the decline, partly offset by higher salaries for the sales team. In the opposite direction, other expenses rose to $2.2 million from $0.6 million. The company linked the increase to higher outstanding debt and interest expense, as well as the cost of writing off materials.
Cash and cash equivalents, restricted cash and marketable securities totaled $18.5 million as of September 30, 2026. That total included $2.7 million at NeuroNOS, within current assets held for sale, and $0.7 million at Beyond Cancer. Restricted cash was $4.8 million on the same date. The company announced a definitive agreement under which UNIVO Pharmaceutical Industries will acquire its controlling stake in NeuroNOS Israel. It said the deal is intended to provide dedicated resources, funding and strategic focus for the subsidiary. The reported liquidity includes amounts associated with the two subsidiaries and restricted cash, according to the company’s breakdown.
Beyond Air maintained its revenue guidance at $8 million for calendar year 2026, excluding revenue from the second system. It set 2027 guidance at between $16 million and $18 million, including expected revenue from the second system, subject to U.S. Food and Drug Administration approval. The FDA is still reviewing the second system’s premarket approval application supplement, which the company submitted in June 2025. The chief executive said the company expects to complete the audit readiness process in mid-December. The system will then be subject to FDA inspection and final approval. The supplement aims to expand the device’s labeling to allow its use during air and ground patient transport.
Beyond Air said LungFit GO received Breakthrough Device designation from the FDA for treating nontuberculous mycobacterial lung disease. But it does not intend to allocate resources to further development before the commercial launch of the second LungFit PH system stabilizes following FDA approval. This comes as the company shifts from a fiscal year ending March 31 to one ending December 31, effective December 31, 2026. The company expects to file a Form 10-K/T for a nine-month transition period ending on that date. XAIR shares closed at $2.52 on November 10, 2026. The closing price reflects a session before the results were released on November 11.